A Cost Analysis of Adverse Event Management of Systemic Therapies for Metastatic Colorectal Cancer on Patients with at Least Two Previous Lines of Treatment in Spain

Ana Fernandez; Beatriz González Astorga; Nuria Rodriguez; María José Safont; Paula Castro Albarrán; María Mareque; Itziar Oyagüez

doi:10.2147/ceor.s586388

journal article Open Access Apr 01, 2026

A Cost Analysis of Adverse Event Management of Systemic Therapies for Metastatic Colorectal Cancer on Patients with at Least Two Previous Lines of Treatment in Spain

Ana Fernandez Beatriz González Astorga Nuria Rodriguez

María José Safont Paula Castro Albarrán María Mareque Itziar Oyagüez

ClinicoEconomics and Outcomes Research Vol. Volume 18 pp. 1-13 · Informa UK Limited

View at Publisher Save 10.2147/ceor.s586388

Topics

No keywords indexed for this article. Browse by subject →

References

41

[1]

[2]

Cáncer colorrectal. Available from: https://www.who.int/es/news-room/fact-sheets/detail/colorectal-cancer. Accessed March 18, 2026.

[3]

Sociedad Española de Oncología Médica (SEOM). Las cifras del cáncer en España, 2025. Available from: https://www.seom.org/images/LAS_CIFRAS_DMC2025.pdf. Accessed March 18, 2026.

[4]

Red Española de Registros de Cáncer (REDECAN). Estimación de la incidencia de cáncer en España. Available from: https://redecan.org/storage/documentation/442e1d1a-4040-4674-81cf-5e6a67af6458.pdf. Accessed October 14, 2025.

[5]

Informe dinámico: cáncer de colon | AECC Observatorio. Available from: https://observatorio.contraelcancer.es/informes/informe-dinamico-cancer-de-colon. Accessed December 18, 2024.

[6]

[7]

Recent trends in SEER age-adjusted incidence rates, 2000-2022. Available from: https://seer.cancer.gov/statistics-network/explorer/application.html. Accessed September 8, 2025.

[8]

Wu Front Oncol (2024) 10.3389/fonc.2024.1480704

[9]

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

A. Cervantes, R. Adam, S. Roselló et al.

Annals of Oncology 2023 10.1016/j.annonc.2022.10.003

[10]

Dasari Lancet (2023) 10.1016/s0140-6736(23)00772-9

[11]

Bouvier Dig Liver Dis (2021) 10.1016/j.dld.2021.01.021

[12]

Arndt J Clin Oncol (2004) 10.1200/jco.2004.02.018

[13]

Röhrl Eur J Oncol Nurs (2020) 10.1016/j.ejon.2019.101679

[14]

Sjövall Colorectal Dis (2023) 10.1111/codi.16332

[15]

Montes Clin Transl Oncol (2022)

[16]

Bekaii-Saab Am J Manag Care (2024) 10.37765/ajmc.2024.89545

[17]

Koopman ESMO Gastrointestinal Oncol (2025) 10.1016/j.esmogo.2025.100214

[18]

Tabernero Am Soc Clin Oncol Educ Book (2022) 10.1200/edbk_349561

[19]

Stintzing ESMO Open (2025) 10.1016/j.esmoop.2025.104297

[20]

European Medicines Agency (EMA). Stivarga EPAR (Product Information). Available from: https://www.ema.europa.eu/en/documents/product-information/stivarga-epar-product-information_en.pdf. Accessed March 18, 2026.

[21]

European Medicines Agency (EMA). Fruzaqla. EPAR (Product information). Available from: https://www.ema.europa.eu/en/documents/product-information/fruzaqla-epar-product-information_en.pdf. Accessed March 18, 2026.

[22]

European Medicines Agency (EMA). Lonsurf. EPAR (Product information). Available from: https://www.ema.europa.eu/en/documents/product-information/lonsurf-epar-product-information_en.pdf. Accessed March 18, 2026.

[23]

European Medicines Agency (EMA). Avastin EPAR (Product information). Available from: https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Accessed March 18, 2026.

[24]

Bachet ESMO Open (2020) 10.1136/esmoopen-2020-000698

[25]

Schuurhuizen Ann Oncol (2017) 10.1093/annonc/mdw617

[26]

Durand Health Econ Rev (2024) 10.1186/s13561-024-00481-y

[27]

European Medicines Agency (EMA). From laboratory to patient: the journey of a medicine assessed by EMA. Available from: https://www.ema.europa.eu/en/documents/other/laboratory-patient-journey-centrally-authorised-medicine_en.pdf. Accessed March 18, 2026.

[28]

Li JAMA (2018) 10.1001/jama.2018.7855

[29]

Axel Lancet (2013) 10.1016/s0140-6736(12)61900-x

[30]

Mayer N Engl J Med (2015) 10.1056/nejmoa1414325

[31]

Prager N Engl J Med (2023) 10.1056/nejmoa2214963

[32]

Paly J Comp Eff Res (2024) 10.57264/cer-2024-0084

[33]

Oblikue - Base de conocimiento de costes y precios del sector sanitario. Available from: http://esalud.oblikue.com/. Accessed March 18, 2026.

[34]

Consejo General de Colegios Oficiales de Farmacéuticos. Base de datos del Conocimiento Sanitario - Bot Plus 2.0. Available from: https://botplusweb.portalfarma.com/. Accessed March 18, 2026.

[35]

BOE-A-2010-8228 Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. Available from: https://www.boe.es/buscar/act.php?id=BOE-A-2010-8228. Accessed March 18, 2026.

[36]

Red Española de Registros de Cáncer (REDECAN). Estimaciones de la incidencia del cáncer en España, 2024. Available from: https://redecan.org/storage/documents/031b5800-a7fe-4c2b-8a09-a38d046365df.pdf. Accessed March 18, 2026.

[37]

Isla Clinicoecon Outcomes Res (2016) 10.2147/ceor.s121093

[38]

Ojeda Br J Cancer (2003) 10.1038/sj.bjc.6601228

[39]

Pericay C, Frías C, Abad A, et al. Análisis coste-efectividad de aflibercept en combinación con FOLFIRI en el tratamiento de pacientes con cáncer colorrectal metastásico.

[40]

Fakih ESMO Open (2024) 10.1016/j.esmoop.2024.103931

[41]

Bonnetain Ann Oncol (2017) 10.1093/annonc/mdx191

Metrics

0

Citations

41

References

Details

Published: Apr 01, 2026
Vol/Issue: Volume 18
Pages: 1-13
License: View

Authors

A

Ana Fernandez

B

Beatriz González Astorga

Paula Castro Albarrán

Pharmacoeconomcis & Outcomes Research Iberia (PORIB), Paseo Joaquín Rodrigo 4 – Letter I, Madrid, Spain.

Cite This Article

Ana Fernandez, Beatriz González Astorga, Nuria Rodriguez, et al. (2026). A Cost Analysis of Adverse Event Management of Systemic Therapies for Metastatic Colorectal Cancer on Patients with at Least Two Previous Lines of Treatment in Spain. ClinicoEconomics and Outcomes Research, Volume 18, 1-13. https://doi.org/10.2147/ceor.s586388

A Cost Analysis of Adverse Event Management of Systemic Therapies for Metastatic Colorectal Cancer on Patients with at Least Two Previous Lines of Treatment in Spain

You May Also Like